(2S,4S)-2,4-dimethyltetrahydro-2H-pyran

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (2S,4S)-2,4-dimethyltetrahydro-2H-pyran
• 英文别名: (2S,4S)-2,4-dimethyloxane
• 化学式: C₇H₁₄O
• 分子量: 114.19
• InChiKey: FPQOQDFWCJXVKF-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011059850A1

  公开（公告）日：2011-05-19

  The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

  本公开涉及制备用于治疗丙型肝炎病毒（HCV）感染的化合物的方法。
• Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20170073343A1

  公开（公告）日：2017-03-16

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R 1 , R 1a , R 1b , R 2 , R 4 , R 5 , R 6 , X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了新颖的咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啉衍生物的化合物(I)及其药学上可接受的盐，其中R1、R1a、R1b、R2、R4、R5、R6、X和Z如规范中所定义。该发明还涉及包含化合物(I)的药物组合物，以及利用这些化合物治疗与LRRK2相关的疾病，如神经退行性疾病包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• [EN] SECO MACROLIDE COMPOUNDS<br/>[FR] COMPOSÉS MACROLIDES DE TYPE SECO
  申请人：FIDELTA D O O

  公开号：WO2017194452A1

  公开（公告）日：2017-11-16

  The present invention relates to seco (opened ring) macrolide compounds of formula (I), to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, to macrolide based macrocycles obtained from said seco macrolide compounds, to the process for preparation of macrolide based macrocycles, to the pharmaceutical compositions comprising macrolide based macrocycles, and to the use of macrolide based macrocycles as therapeutic agents.

  本发明涉及具有式(I)的开环（seco）大环内酯化合物，其制备方法，所述开环大环内酯化合物作为制备基于大环内酯的中间体的用途，从所述开环大环内酯化合物获得的基于大环内酯的大环内酯，制备基于大环内酯的大环内酯的方法，包括基于大环内酯的大环内酯的制药组合物，以及基于大环内酯的大环内酯作为治疗剂的用途。
• [EN] CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS<br/>[FR] PROCÉDÉS CONVERGENTS DE PRÉPARATION D'AGENTS ANTIBACTÉRIENS MACROLIDES
  申请人：CEMPRA PHARMACEUTICALS INC

  公开号：WO2014145210A1

  公开（公告）日：2014-09-18

  The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain.

  本发明涉及制备酮酸类抗菌剂的过程。特别是，本发明涉及中间体和制备酮酸类化合物的过程，其中包括1,2,3-三唑取代的侧链。
• MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY
  申请人：NAPOLETANO Mauro

  公开号：US20090054357A1

  公开（公告）日：2009-02-26

  Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

  本文描述了具有抗炎活性的大环内酯化合物，尤其是缺乏3位克拉多糖的大环内酯衍生物，具有抗炎活性，其药学上可接受的盐和含有它们作为活性成分的制药组合物。

表征谱图